[go: up one dir, main page]

JP3345260B2 - Permselective hollow fiber membrane - Google Patents

Permselective hollow fiber membrane

Info

Publication number
JP3345260B2
JP3345260B2 JP09845796A JP9845796A JP3345260B2 JP 3345260 B2 JP3345260 B2 JP 3345260B2 JP 09845796 A JP09845796 A JP 09845796A JP 9845796 A JP9845796 A JP 9845796A JP 3345260 B2 JP3345260 B2 JP 3345260B2
Authority
JP
Japan
Prior art keywords
hollow fiber
fiber membrane
molecular weight
present
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP09845796A
Other languages
Japanese (ja)
Other versions
JPH09285536A (en
Inventor
昭治 水谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14220241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3345260(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP09845796A priority Critical patent/JP3345260B2/en
Priority to CA002202969A priority patent/CA2202969C/en
Priority to US08/837,475 priority patent/US6013182A/en
Priority to EP97302660A priority patent/EP0801973A1/en
Publication of JPH09285536A publication Critical patent/JPH09285536A/en
Application granted granted Critical
Publication of JP3345260B2 publication Critical patent/JP3345260B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Landscapes

  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は選択透過性中空糸膜
に関するものである。更に詳しくは、特定の水透過性能
および透析器における特定のデキストランの総括物質移
動係数、かつアルブミンの篩係数を有し、優れた分離性
能を呈する選択透過性を有するものであり、血液透析、
血液濾過透析等の血液処理に適し、特に中高分子量領域
の有害物質を除去するのに適した選択透過性中空糸膜を
提供するものである。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a selectively permeable hollow fiber membrane. More specifically, it has a specific water permeation performance and an overall mass transfer coefficient of a specific dextran in a dialyzer, and a sieving coefficient of albumin, and has selective permeability exhibiting excellent separation performance, and hemodialysis,
It is an object of the present invention to provide a selectively permeable hollow fiber membrane suitable for blood treatment such as hemofiltration dialysis, and particularly suitable for removing harmful substances in a medium-high molecular weight region.

【0002】[0002]

【従来の技術】選択透過性中空糸膜は、逆浸透や血液透
析等において従来より実用的に使用されてきている。特
に腎不全患者の血液を浄化するために、現在では中空糸
型血液透析器がよく使用されている。これは筐体の中に
透析膜、例えば、中空糸の膜を多数本、収納し、その中
空内部に患者の血液を流し、外部、すなわち、中空糸間
隙部に透析液を流して、中空糸膜壁を介して透析によっ
て、血液中の老廃物を除去し電解質濃度を是正するとと
もに、中空糸内外に圧力差を与えて限外濾過によって血
液中の余剰水分を除去するものである。更に、血液中か
ら血漿のみを分離し、あるいは、その血漿の中から特定
成分を除去して自己免疫疾患などを治療するために、中
空糸が使用されることもある。また最近になってタンパ
ク透過性血液透析やタンパク透過性血液濾過透析に中空
糸を用いることによって治療効果が得られることが確認
されるようになってきている。
2. Description of the Related Art Permselective hollow fiber membranes have been practically used in reverse osmosis and hemodialysis. In particular, hollow fiber hemodialyzers are often used at present for purifying blood of patients with renal failure. In this method, a dialysis membrane, for example, a large number of hollow fiber membranes, is housed in a housing, blood of a patient flows in the hollow, and a dialysate flows in the outside, that is, a hollow fiber gap, and a hollow fiber is formed. In addition to removing waste in blood and correcting electrolyte concentration by dialysis through the membrane wall, a pressure difference is applied inside and outside the hollow fiber to remove excess water in blood by ultrafiltration. Furthermore, hollow fibers are sometimes used to separate plasma alone from blood or to remove specific components from the plasma to treat autoimmune diseases and the like. Recently, it has been confirmed that a therapeutic effect can be obtained by using hollow fibers in protein-permeable hemodialysis or protein-permeable hemofiltration dialysis.

【0003】このように血液処理用の中空糸は目的に応
じて特定の物質を選択的に透過せしめなければならな
い。その性能は、中空糸の素材、ポロシテイ(孔の大き
さ、数など)、膜厚などによって決定される。
As described above, a hollow fiber for blood treatment must selectively allow a specific substance to permeate according to the purpose. The performance is determined by the material of the hollow fiber, the porosity (the size and number of holes), the film thickness, and the like.

【0004】ところで、近年、透析患者の長期合併症と
関連し、透析アミロイドシスの原因物質と考えられるβ
2 ―MG(ミクログロブリン)(分子量11,800)
掻痒感、高脂血症と関係すると考えられる副甲状腺ホル
モン(分子量約9,500)、貧血に関与する赤芽球抑
制因子(分子量約1,000)、関節痛、骨痛に係わる
と考えられる分子量2〜4万の物質、など比較的中高分
子量領域の有害物質の除去の必要性がさけばれている。
一方、人体に必須のアルブミン(分子量66,000)
の損失は極力避けなければならない。すなわち、分子量
4〜5万以下の物質の透過性に優れ、一方分子量6万以
上の物質の阻止性のよい分画分子量のシャープカット性
の良好な選択透過性膜が望まれている。
[0004] In recent years, β which is considered to be a causative substance of dialysis amyloidosis is associated with long-term complications of dialysis patients.
2- MG (microglobulin) (molecular weight 11,800)
It is thought to be related to parathyroid hormone (molecular weight of about 9,500), which is thought to be associated with pruritus and hyperlipidemia, erythroblast inhibitory factor (molecular weight of about 1,000) involved in anemia, joint pain and bone pain The need to remove harmful substances in the relatively high molecular weight region, such as substances having a molecular weight of 20,000 to 40,000, has been avoided.
On the other hand, albumin essential for the human body (molecular weight 66,000)
Loss must be avoided as much as possible. That is, there is a demand for a permselective membrane which is excellent in permeability of substances having a molecular weight of 40,000 or less and 50,000 or less, and which has good rejection of substances having a molecular weight of 60,000 or more and a good sharp cut property of a cut molecular weight.

【0005】しかるに、従来、ポリサルホンなどの合成
高分子では、例えば特公平2−18695号や特公平5
−54373号に見られるように、比較的上記要求を満
たしたものが得られているが、セルロース誘導体特にト
リアセテートでは、例えば特公昭58−24165号に
見られるように、中空糸を湿式紡糸するときの芯剤に、
流動パラフィン、高級アルコール、イソプロピルミリス
テートなど、トリアセテート紡糸原液に対し凝固性のな
いものを使用するために、紡糸原液におけるトリアセテ
ートの濃度を高め、紡糸時の曳糸性を高くせざるを得な
い。また、紡糸原液をノズルから出糸後、中空糸外面か
ら凝固液で固化させるために、中空糸外面に緻密構造の
層が形成される。
However, conventionally, synthetic polymers such as polysulfone are disclosed in, for example, Japanese Patent Publication No.
As can be seen in JP-A-54373, those relatively satisfying the above requirements have been obtained. However, in the case of cellulose derivatives, especially triacetate, for example, as shown in JP-B-58-24165, when a hollow fiber is wet-spun. For the core agent,
In order to use non-coagulable triacetate spinning solution such as liquid paraffin, higher alcohol, and isopropyl myristate, it is necessary to increase the concentration of triacetate in the spinning solution to increase spinnability during spinning. In addition, a layer having a dense structure is formed on the outer surface of the hollow fiber in order to solidify the spinning stock solution from the nozzle and then solidify the outer surface of the hollow fiber with the coagulating liquid.

【0006】これらの理由により、従来、セルロース誘
導体中空糸は、合成ポリマーの膜に比し、構造の緻密層
と多孔層の密度差が小さく、全体として均一層に近く、
物質の透過性能が十分とはいえなかった。そのために膜
の厚さを減少せしめ、透過性の向上を図ってきたが、十
分なものとはいえない。更に、膜構造の緻密層と多孔層
の密度差が不明確なために、透過物質の分画特性におい
ても、改良の余地のあるものであった。
[0006] For these reasons, conventionally, a cellulose derivative hollow fiber has a smaller difference in density between a dense layer and a porous layer in structure than a synthetic polymer membrane, and is close to a uniform layer as a whole.
The permeability of the substance was not sufficient. For this purpose, the thickness of the film has been reduced and the permeability has been improved, but this is not sufficient. Furthermore, since the density difference between the dense layer and the porous layer having a membrane structure is unclear, there is room for improvement in the fractionation characteristics of the permeated substance.

【0007】[0007]

【発明の目的】本発明は、このような従来技術の問題点
を解決することを目的とするものであって、セルロース
誘導体のポリマーを使用して従来の合成ポリマーの構造
に近い粗密構造を与え、高い分子量分画特性を付与する
ことである。特に血液透析や血液濾過透析においてβ2
―MG等の中高分子量領域の有害物質の除去とアルブミ
ンなどの有用物質の流出阻止を高めることが可能な選択
透過性中空糸膜を提供することを目的としている。
SUMMARY OF THE INVENTION An object of the present invention is to solve such problems of the prior art, and to provide a coarse-dense structure close to the structure of a conventional synthetic polymer using a polymer of a cellulose derivative. And high molecular weight fractionation properties. Especially in hemodialysis and hemofiltration dialysis, β 2
-It is an object of the present invention to provide a selectively permeable hollow fiber membrane capable of removing harmful substances in a medium-high molecular weight region such as MG and preventing outflow of useful substances such as albumin.

【0008】[0008]

【発明の構成】本発明者は、かかる目的を達成するため
に鋭意研究した結果、特定の水透過性能とデキストラン
の総括物質移動係数及びアルブミンの篩係数を有する中
空糸を用いた血液浄化器が飛躍的に高められた分離性能
を発揮することを見い出し、本発明に到達した。
The present inventors have conducted intensive studies to achieve the above object, and as a result, a blood purifier using a hollow fiber having a specific water permeation performance, an overall mass transfer coefficient of dextran and a sieve coefficient of albumin has been developed. The present inventors have found that a dramatically improved separation performance is exhibited, and reached the present invention.

【0009】すなわち、本発明は、選択透過性を有する
中空糸膜において、37℃における水透過性能(UF
R)が、200ml/Hr,mmHg,m2 以上であ
り、かつ該中空糸膜を透析器として組立て測定した、分
子量10,000のデキストランの0.1重量%を含む
水溶液を使用した該デキストランの総括物質移動係数
(K0 )が6.7×10-5cm/sec以上、牛血漿を
1時間灌流した後のアルブミンの篩係数(S.C.)が
0.02以下であることを特徴とする実質的にセルロー
ス誘導体からなる選択透過性中空糸膜を提供するもので
ある。
That is, according to the present invention, a water permeable performance at 37 ° C. (UF
R) is not less than 200 ml / Hr, mmHg, m 2 , and the hollow fiber membrane was assembled and measured as a dialyzer. The dextran using an aqueous solution containing 0.1% by weight of dextran having a molecular weight of 10,000 was measured. The overall mass transfer coefficient (K 0 ) is 6.7 × 10 −5 cm / sec or more, and the sieving coefficient (SC) of albumin after perfusing bovine plasma for 1 hour is 0.02 or less. The present invention provides a selectively permeable hollow fiber membrane substantially consisting of a cellulose derivative.

【0010】以下、本発明について更に詳細に説明す
る。
Hereinafter, the present invention will be described in more detail.

【0011】すなわち、本発明における中空糸膜は、選
択透過性を有するものであり、その素材としては、セル
ロース誘導体、特にアセチルセルロースであり、その中
でも一般的に使用されるものとしては、実質的にセルロ
ースジアセテート、セルローストリアセテートからなる
高分子である。なお、実質的とは、このセルロース誘導
体の特性を損わない範囲で、他の高分子、添加物などを
含有してもよいことを意味する。
That is, the hollow fiber membrane of the present invention has a selective permeability, and is made of a cellulose derivative, particularly acetylcellulose. And a polymer composed of cellulose diacetate and cellulose triacetate. Note that “substantially” means that other polymers, additives, and the like may be contained as long as the properties of the cellulose derivative are not impaired.

【0012】また本発明の中空糸膜の膜壁の構造に関し
ては、物質の分離透過特性と機械特性を機能分担させる
ような、極薄緻密層と、機械的に流体圧力に耐えられる
が、物質の透過抵抗には殆んどならない多孔層とを合せ
持つような、従来、合成高分子で実現されていた2層又
は多層構造が好ましい。特に、中空糸膜の内面を通して
血液を処理する場合には、少くとも中空糸内面に緻密層
があるのが望ましい。内面に多孔層があると、その部分
に血中蛋白が付着したり、あるいは孔中に侵入したりし
て、物質透過の阻害になる懸念がある。
The structure of the membrane wall of the hollow fiber membrane of the present invention is characterized by an ultra-thin dense layer that functions to separate and permeate the separation and permeation characteristics of the substance and the mechanical properties, and is capable of mechanically withstanding fluid pressure. A two-layer or multi-layer structure conventionally realized by a synthetic polymer, which has a porous layer having almost no permeation resistance, is preferable. In particular, when blood is processed through the inner surface of the hollow fiber membrane, it is desirable that there is a dense layer at least on the inner surface of the hollow fiber. If there is a porous layer on the inner surface, there is a concern that blood proteins may adhere to that portion or penetrate into the pores, thereby impeding the permeation of substances.

【0013】中空糸膜の膜厚は、一般に物質の透過性か
らみれば薄いのが望ましいが、本発明に係わるような2
層以上の構造のものでは、多孔層を有するために機械的
強度の点より30μm以上が好ましい。なお、中空糸膜
の内径は100〜300μm、更には150〜250μ
mが好ましい。
The thickness of the hollow fiber membrane is generally desirably small in view of the permeability of the substance.
In the case of a structure having two or more layers, the thickness is preferably 30 μm or more from the viewpoint of mechanical strength because of having a porous layer. The inner diameter of the hollow fiber membrane is 100 to 300 μm, and more preferably 150 to 250 μm.
m is preferred.

【0014】また、本発明の中空糸膜の37℃における
水透過性能(UFR)は200ml/hr,mmHg,
2 以上である。従来の比較的均一構造の膜では、この
ような高レベルの水透過性能は得られ難かった。このよ
うなUFRをもたせることで、一定量の除水をするため
のTMP(中空糸膜の両側にかかる差圧)を低めること
ができ、中空糸膜への血中蛋白質の付着などが抑えられ
る。例えば、牛血を用いた透析において、有効面積1.
5m2 の透析器で4時間に2L(リッター)の除水をす
るとき、従来のセルロースアセテート系中空糸を用いた
透析器では20〜30mmHgのTMPが必要である
が、本発明の中空糸を用いた透析器では約1/2の20
mmHg未満、例えば10mmHg以上20mmHg未
満のTMPで十分である。また、水透過性が高いという
ことは水分子だけでなく、尿素、クレアチニン、尿酸な
どの低分子物質の透過性も高いことを意味し、透析器と
しては基本的性能として望ましいものである。
The water permeability (UFR) at 37 ° C. of the hollow fiber membrane of the present invention is 200 ml / hr, mmHg,
m 2 or more. It was difficult to obtain such a high level of water permeation performance with a conventional membrane having a relatively uniform structure. By providing such a UFR, TMP (differential pressure applied to both sides of the hollow fiber membrane) for removing a certain amount of water can be reduced, and adhesion of blood proteins to the hollow fiber membrane can be suppressed. . For example, in dialysis using bovine blood, the effective area 1.
When removing water of 2 L (liter) in 4 hours with a dialyser of 5 m 2, a dialyser using a conventional cellulose acetate hollow fiber requires a TMP of 20 to 30 mmHg. In the dialyzer used, about 1/2 of 20
A TMP of less than mmHg, for example, 10 mmHg or more and less than 20 mmHg is sufficient. Further, high water permeability means that not only water molecules but also low molecular substances such as urea, creatinine, uric acid and the like are permeable, which is desirable as a basic performance for a dialyzer.

【0015】また、本発明の中空糸膜の特徴の1つとし
て、その中空糸束を用いて組み立てた透析器においてデ
キストラン10,000の総括物質移動係数K0 が6.
7×10-5cm/sec以上であることがあげられる。
なお、かかるK0 の測定方法としては、円筒状容器に約
52%の充填率で中空糸束を充填して両端を接着剤でシ
ール固化した後切断して中空部を開口することにより
1.5m2 の有効膜表面積の透析器を組み立てたものを
用いて、37℃において血液側すなわち中空部側に0.
1重量%のデキストラン10,000の水溶液を200
ml/分で流し、透析液側すなわち中空糸間隙部側に水
を500ml/分で流した場合の血液側の流出液中の濃
度を測定することによって、下記式によりK0 が得られ
る。サンプリング液中のデキストラン濃度は、例えばア
ンスロン―硫酸法により測定する。
One of the features of the hollow fiber membrane of the present invention is that the total mass transfer coefficient K 0 of dextran 10,000 in a dialyzer assembled using the hollow fiber bundle is 6.
It is 7 × 10 −5 cm / sec or more.
The K 0 can be measured by filling a cylindrical container with a bundle of hollow fibers at a filling rate of about 52%, solidifying both ends with an adhesive, cutting, and opening the hollow portion. Using a dialyzer assembled with an effective membrane surface area of 5 m 2 , at 0 ° C. at 37 ° C., on the blood side, that is, on the hollow side.
A 1% by weight aqueous solution of 10,000 dextran was added to 200
K 0 is obtained by the following equation by measuring the concentration in the effluent on the blood side when water is flowed at 500 ml / min on the dialysate side, that is, on the hollow fiber gap side, at 500 ml / min. The dextran concentration in the sampling solution is measured by, for example, an anthrone-sulfuric acid method.

【0016】[0016]

【数1】 (Equation 1)

【0017】本発明の中空糸膜のK0 としては6.7×
10-5cm/sec以上、更に好ましくは9.2×10
-5cm/sec以上が実用上好ましい。
The K 0 of the hollow fiber membrane of the present invention is 6.7 ×
10 −5 cm / sec or more, more preferably 9.2 × 10
-5 cm / sec or more is practically preferable.

【0018】更に本発明に係わる中空糸膜は、その中空
糸束を用いて組み立てた透析器において、血液側に牛血
漿を1時間灌流した後に測定したアルブミンの篩係数が
0.02以下であることを特徴としている。好ましくは
0.01以下であり、水、低分子物質及び分子量10,
000のデキストランの物質透過性が良好であるのに拘
らず、分子量が約66,000のアルブミンの中空糸膜
を通じての透過性は十分に阻止されているものであり、
これらの分子量の間にシャープな分画特性を有してい
る。
Furthermore, in the hollow fiber membrane according to the present invention, the sieving coefficient of albumin measured after perfusing bovine plasma on the blood side for one hour in a dialyzer assembled using the hollow fiber bundle is 0.02 or less. It is characterized by: It is preferably 0.01 or less, and water, a low molecular weight substance and a molecular weight of 10,
Despite the good material permeability of dextran of 000, the permeability of albumin having a molecular weight of about 66,000 through the hollow fiber membrane is sufficiently inhibited,
It has sharp fractionation characteristics between these molecular weights.

【0019】このように本発明の中空糸膜は、血液透析
器や血液濾過透析に使用した場合に、β2 ―MGなどの
中高分子量の領域の有害物質の除去性能が高く、かつ低
分子量領域の有害物質の除去性能も優れている上に、人
体に有益なアルブミンの損失量が少ないという選択透過
性に優れたものである。
As described above, when the hollow fiber membrane of the present invention is used in a hemodialyzer or hemofiltration dialysis, it has a high ability to remove harmful substances in a medium-high molecular weight region such as β 2 -MG and a low molecular weight region. In addition to the excellent performance of removing harmful substances, the selective permeation of albumin, which is beneficial to the human body, is small.

【0020】かかる本発明の中空糸膜の製造方法は特に
限定されるものではないが、望ましくはセルロース誘導
体を有機溶剤に溶解した紡糸原液を、芯剤として水溶液
を用いて、チューブインオリフィス状ノズルより吐出さ
せ、気体中を通過後、水溶性凝固液中に通し固化させる
方式が採用される。
Although the method for producing the hollow fiber membrane of the present invention is not particularly limited, a tube-in-orifice-shaped nozzle is preferably prepared by using a spinning solution obtained by dissolving a cellulose derivative in an organic solvent and using an aqueous solution as a core agent. A method is adopted in which the liquid is discharged more, passes through a gas, and then passes through a water-soluble coagulating liquid and solidifies.

【0021】[0021]

【実施例】以下本発明について実施例をあげて更に具体
的に説明するが、本発明は、これらの実施例によって何
ら限定されるものではない。
EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited to these examples.

【0022】[実施例1〜8、比較例1〜3]セルロー
ストリアセテート13部とトリエチレングリコール20
部を、ジメチルスルホオキシド67部に均一溶解したも
のを紡糸原液として、チューブインオリフィス型ノズル
より、ジメチルスルホオキシドの水溶液を芯剤として、
空気中に吐出させた後、凝固液の中に導いて固化させ、
水洗、グリセリン付着処理後、捲取った。得られた中空
糸膜を乾燥後束状にして、円管状の容器内に挿入充填し
て、両端をポリウレタンで接着固定し、有効面積が約
1.5m2 の血液透析器を作成し、in vitroで
の水透過性能(UFR)とデキストラン10,000の
総括物質移動係数(K0 )及び牛血漿を用いたアルブミ
ンの篩係数(S.C.)を測定した。一方、牛血漿にβ
2 ―MGを0.05%溶解したものを用い、血液側を2
00ml/分で流し、透析液を500ml/分で流し
て、約4時間の血液透析を行った。
Examples 1 to 8, Comparative Examples 1 to 3 13 parts of cellulose triacetate and triethylene glycol 20
Part was uniformly dissolved in 67 parts of dimethylsulfoxide as a spinning stock solution, and a tube-in orifice type nozzle was used as an aqueous solution of dimethylsulfoxide as a core agent.
After being discharged into the air, it is guided into the coagulating liquid and solidified,
After washing with water and glycerin adhesion treatment, it was wound up. The obtained hollow fiber membranes are dried, bundled, inserted and filled in a cylindrical container, and both ends are adhered and fixed with polyurethane to prepare a hemodialyzer having an effective area of about 1.5 m 2. The water permeability (UFR) in vitro, the overall mass transfer coefficient (K 0 ) of dextran 10,000 and the sieving coefficient (SC) of albumin using bovine plasma were measured. On the other hand, β
2 -Use a solution of 0.05% of MG, and
The blood was dialyzed at a flow rate of 00 ml / min and the dialysate was flowed at a flow rate of 500 ml / min for approximately 4 hours.

【0023】透析前後でのβ2 ―MGの除去率、すなわ
The removal rate of β 2 -MG before and after dialysis, ie,

【0024】[0024]

【数2】 (Equation 2)

【0025】を算出した後、除水によるβ2 ―MGの濃
縮効果を補正した。
After the calculation, the concentration effect of β 2 -MG due to water removal was corrected.

【0026】また、透析開始直後と4時間透析終了直前
でのUFRの低下率、すなわち
The UFR reduction rate immediately after the start of dialysis and immediately before the end of dialysis for 4 hours, ie,

【0027】[0027]

【数3】 (Equation 3)

【0028】を算出した。更に透析終了後、全透析液中
のアルブミンの量を測定しアルブミン漏出量とした。
Was calculated. Further, after the dialysis was completed, the amount of albumin in all the dialysate was measured and defined as the amount of albumin leakage.

【0029】表1は紡糸の条件とin vitroの特
性値及び透析性能を示したものである。本発明の中空糸
は、β2 ―MGの除去率が大きく、UFRの経時変化お
よびアルブミンの透析液への漏出量が小さくなってい
る。
Table 1 shows spinning conditions, in vitro characteristic values, and dialysis performance. The hollow fiber of the present invention has a large removal rate of β 2 -MG, a small change in UFR with time, and a small amount of albumin leaked into the dialysate.

【0030】[0030]

【表1】 [Table 1]

【0031】本発明の中空糸膜は、その集束体を用いて
血液浄化器を組み立てた場合、β2―MG等の中高分子
量領域の有害物質の除去率が高いのみならず、除水性能
の透析中の経時変化が小さく、更にアルブミンの透析液
中への漏出量が少ないという優れた効果を奏するもので
ある。
When the hollow fiber membrane of the present invention is used to assemble a blood purifier using the bundle, not only the removal rate of harmful substances in the medium-high molecular weight region such as β 2 -MG is high, but also the water removal performance is improved. This is an excellent effect that changes over time during dialysis are small and the amount of albumin leaking into the dialysate is small.

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 平2−211229(JP,A) 特開 平7−148252(JP,A) 特開 平7−278948(JP,A) 特開 平8−38598(JP,A) 特開 平8−970(JP,A) 特開 平9−70525(JP,A) 特公 平3−76970(JP,B2) 特公 平8−29231(JP,B2) (58)調査した分野(Int.Cl.7,DB名) A61M 1/16 - 1/18 B01D 69/02,69/08,71/16 ──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-2-211229 (JP, A) JP-A-7-148252 (JP, A) JP-A-7-278948 (JP, A) JP-A 8- 38598 (JP, A) JP-A-8-970 (JP, A) JP-A-9-70525 (JP, A) JP-B3-76970 (JP, B2) JP-B 8-29231 (JP, B2) (58) Field surveyed (Int.Cl. 7 , DB name) A61M 1/16-1/18 B01D 69 / 02,69 / 08,71 / 16

Claims (2)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 内面に緻密層、その外側に多孔層を有す
る選択透過性を有する実質的にセルローストリアセテー
トからなる中空糸膜において、37℃における水透過性
能(UFR)が、200ml/Hr,mmHg,m2
上であり、かつ該中空糸膜を透析器として組立て測定し
た、分子量10,000のデキストランの0.1重量%
を含む水溶液を使用した該デキストランの総括物質移動
係数(K0 )が6.7×10-5cm/sec以上、牛血
漿を1時間灌流した後のアルブミンの篩係数(S.
C.)が0.02以下であることを特徴とする実質的に
セルローストリアセテートからなる血液透析用の選択透
過性中空糸膜。
1. A substantially permeable cellulose triacetate having a dense layer on the inner surface and a porous layer on the outer surface.
In the hollow fiber membrane made of bets, water permeability (UFR) is at 37 ° C., and the 200ml / Hr, mmHg, m 2 or more and the hollow fiber membrane was assembled measured as dialyzer, a molecular weight of 10,000 dextran 0.1% by weight of
The mass transfer coefficient (K 0 ) of the dextran using an aqueous solution containing 6.7 × 10 −5 cm / sec or more, and the sieving coefficient of albumin (S.
C. ) Is not more than 0.02.
A permselective hollow fiber membrane for hemodialysis comprising cellulose triacetate .
【請求項2】 該選択透過性中空糸膜が、膜厚30μm
以上からなる特許請求の範囲第1項に記載の選択透過性
中空糸膜。
2. The selectively permeable hollow fiber membrane has a thickness of 30 μm.
The selectively permeable hollow fiber membrane according to claim 1, comprising the above.
JP09845796A 1996-04-19 1996-04-19 Permselective hollow fiber membrane Ceased JP3345260B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP09845796A JP3345260B2 (en) 1996-04-19 1996-04-19 Permselective hollow fiber membrane
CA002202969A CA2202969C (en) 1996-04-19 1997-04-17 Selectively permeable hollow fiber membrane and process for producing same
US08/837,475 US6013182A (en) 1996-04-19 1997-04-18 Selectively permeable hollow fiber membrane and process for producing same
EP97302660A EP0801973A1 (en) 1996-04-19 1997-04-18 Selectively permeable hollow fiber membrane and process for producing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP09845796A JP3345260B2 (en) 1996-04-19 1996-04-19 Permselective hollow fiber membrane

Publications (2)

Publication Number Publication Date
JPH09285536A JPH09285536A (en) 1997-11-04
JP3345260B2 true JP3345260B2 (en) 2002-11-18

Family

ID=14220241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09845796A Ceased JP3345260B2 (en) 1996-04-19 1996-04-19 Permselective hollow fiber membrane

Country Status (1)

Country Link
JP (1) JP3345260B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102247345B1 (en) * 2019-07-12 2021-05-03 한국화학연구원 Hollow fiber membrane with improved mechanical strength, and method for manufacturing the same

Also Published As

Publication number Publication date
JPH09285536A (en) 1997-11-04

Similar Documents

Publication Publication Date Title
JP2001170167A (en) Method of manufacturing dialyzer and method of sterilization
JP4061798B2 (en) Semipermeable membrane for blood treatment and dialyzer for blood treatment using the same
CS226188B2 (en) Dialysing diaphragm in the form of flat foil,tubular foil or hollow filament made of cellulose regenerated by using cuoxam process
WO1997034687A1 (en) Hollow yarn membrane used for blood purification and blood purifier
US6013182A (en) Selectively permeable hollow fiber membrane and process for producing same
US5736046A (en) High-flux hollow-fiber membrane with enhanced transport capability and process for making same
JP3253861B2 (en) Permselective hollow fiber membrane
JP3295321B2 (en) Permselective hollow fiber membrane
JPH10263375A (en) Selective permeable hollow fiber membrane
JP3253867B2 (en) Permselective hollow fiber membrane
JP3345260B2 (en) Permselective hollow fiber membrane
JP3253885B2 (en) Permselective hollow fiber membrane
JP3424810B2 (en) High performance blood purification membrane
JPH09308685A (en) Hollow fiber membrane for blood purification and blood purifying device
JP3236233B2 (en) Method for producing selectively permeable hollow fiber membrane
JP3651121B2 (en) Permselective separation membrane
JP4003982B2 (en) Polysulfone-based selectively permeable separation membrane
JP3295314B2 (en) Permselective hollow fiber membrane
JP3205268B2 (en) Method for producing selectively permeable hollow fiber membrane
JPH09308684A (en) Selective separating membrane
JP2812890B2 (en) Blood purifier
JP2894475B2 (en) Hemodialysis machine using hollow fiber membrane
JP2000107577A (en) Production of permselective hollow fiber membranes
JP3205267B2 (en) Method for producing selectively permeable hollow fiber membrane
JP2002186667A (en) Hollow fiber type hemodialyzer

Legal Events

Date Code Title Description
RVOP Cancellation by post-grant opposition